ArticleInternational journal of general medicine2026
Diagnostic Performance of Platelet-to-Lymphocyte Ratio and CA19-9 Added to EUS-FNA for Solid Pancreatic Lesions: A Single-Center Retrospective Study.
Article in International journal of general medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To evaluate the incremental diagnostic value of the platelet-to-lymphocyte ratio (PLR) and carbohydrate antigen 19-9 (CA19-9) when combined with endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) in patients with solid pancreatic lesions. Patients and Methods: This retrospective single-center study included 127 consecutive patients who underwent EUS-FNA for solid pancreatic lesions between December 29, 2020, and October 23, 2023. Final diagnoses were established using a reference standard independent of the index EUS-FNA. Malignancy was confirmed by surgical pathology, independent cytologic or histologic evidence, or unequivocal radiologic progression or metastasis. Non-malignancy was established by independent benign pathology or lesion stability or regression without anticancer therapy during at least 24 months of clinical and imaging follow-up. Results: Among 127 patients, 80 had malignant lesions and 47 had non-malignant lesions. EUS-FNA achieved an accuracy of 91.3%, sensitivity of 93.8%, specificity of 87.2%, positive predictive value of 92.6%, and negative predictive value of 89.1%. CA19-9 levels were significantly higher in malignant than in non-malignant lesions (median [IQR], 197.21 [9.51-928.36] vs 14.30 [3.97-211.02] U/mL; Conclusion: EUS-FNA demonstrated high diagnostic accuracy for solid pancreatic lesions. PLR and CA19-9 provided complementary diagnostic value, and the three-variable model showed high diagnostic performance after internal validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.